ATE146361T1 - Therapeutische mittel für die behandlungder resistenz gegen arzneimittel bei krebs - Google Patents

Therapeutische mittel für die behandlungder resistenz gegen arzneimittel bei krebs

Info

Publication number: ATE146361T1
Authority: AT; Austria
Prior art keywords: treatment; cancer; therapeutic agents; drug resistance; dihydrocinchonine
Prior art date: 1991-02-25

Application number

AT92905338T

Other languages

English (en)

Inventor

Bruno Chauffert

Philippe Genne

Gilles Gutierrez

Rolland-Yves Mauvernay

Original Assignee

Debiopharm Sa

Patrinove

Inst Nat Sante Rech Med

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-02-25

Filing date

1992-02-24

Publication date

1997-01-15

1991-02-25 Priority claimed from CH57691A external-priority patent/CH682050A5/fr

1991-12-02 Priority claimed from CH352291A external-priority patent/CH683238A5/fr

1992-02-24 Application filed by Debiopharm Sa, Patrinove, Inst Nat Sante Rech Med filed Critical Debiopharm Sa

1997-01-15 Application granted granted Critical

1997-01-15 Publication of ATE146361T1 publication Critical patent/ATE146361T1/de

Links

206010028980 Neoplasm Diseases 0.000 title abstract 4
206010059866 Drug resistance Diseases 0.000 title 1
201000011510 cancer Diseases 0.000 title 1
239000003814 drug Substances 0.000 title 1
229940124597 therapeutic agent Drugs 0.000 title 1
LJOQGZACKSYWCH-LHHVKLHASA-N (s)-[(2r,4s,5r)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol Chemical compound C1=C(OC)C=C2C([C@H](O)[C@H]3C[C@@H]4CCN3C[C@@H]4CC)=CC=NC2=C1 LJOQGZACKSYWCH-LHHVKLHASA-N 0.000 abstract 2
WFJNHVWTKZUUTR-QAMTZSDWSA-N Hydrocinchonine Chemical compound C1=CC=C2C([C@H](O)[C@H]3C[C@@H]4CCN3C[C@@H]4CC)=CC=NC2=C1 WFJNHVWTKZUUTR-QAMTZSDWSA-N 0.000 abstract 2
LJOQGZACKSYWCH-AFHBHXEDSA-N Hydroquinidine Natural products C1=C(OC)C=C2C([C@@H](O)[C@H]3C[C@@H]4CCN3C[C@@H]4CC)=CC=NC2=C1 LJOQGZACKSYWCH-AFHBHXEDSA-N 0.000 abstract 2
KMPWYEUPVWOPIM-UHFFFAOYSA-N cinchonidine Natural products C1=CC=C2C(C(C3N4CCC(C(C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-UHFFFAOYSA-N 0.000 abstract 2
KMPWYEUPVWOPIM-LSOMNZGLSA-N cinchonine Chemical compound C1=CC=C2C([C@@H]([C@H]3N4CC[C@H]([C@H](C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-LSOMNZGLSA-N 0.000 abstract 2
LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 abstract 2
WFJNHVWTKZUUTR-UHFFFAOYSA-N dihydrocinchonidine Natural products C1=CC=C2C(C(O)C3CC4CCN3CC4CC)=CC=NC2=C1 WFJNHVWTKZUUTR-UHFFFAOYSA-N 0.000 abstract 2
229960000811 hydroquinidine Drugs 0.000 abstract 2
230000036457 multidrug resistance Effects 0.000 abstract 2
229940127089 cytotoxic agent Drugs 0.000 abstract 1
239000002254 cytotoxic agent Substances 0.000 abstract 1
231100000599 cytotoxic agent Toxicity 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT92905338T 1991-02-25 1992-02-24 Therapeutische mittel für die behandlungder resistenz gegen arzneimittel bei krebs ATE146361T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CH57691A CH682050A5 (en)	1991-02-25	1991-02-25	Use of cinchonine, di:hydro:cinchonine or hydro:quinidine
CH352291A CH683238A5 (fr)	1991-12-02	1991-12-02	Hydroquinidine, comme agent thérapeutique et son utilisation dans une composition pharmaceutique.

Publications (1)

Publication Number	Publication Date
ATE146361T1 true ATE146361T1 (de)	1997-01-15

Family

ID=25685005

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT92905338T ATE146361T1 (de)	1991-02-25	1992-02-24	Therapeutische mittel für die behandlungder resistenz gegen arzneimittel bei krebs

Country Status (9)

Country	Link
US (1)	US5635515A (de)
EP (1)	EP0526608B1 (de)
JP (1)	JPH06505991A (de)
AT (1)	ATE146361T1 (de)
AU (1)	AU649787B2 (de)
CA (1)	CA2081343C (de)
DE (1)	DE69215999T2 (de)
ES (1)	ES2097905T3 (de)
WO (1)	WO1992014467A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5436243A (en) *	1993-11-17	1995-07-25	Research Triangle Institute Duke University	Aminoanthraquinone derivatives to combat multidrug resistance
US5866699A (en) *	1994-07-18	1999-02-02	Hybridon, Inc.	Oligonucleotides with anti-MDR-1 gene activity
CA2221444A1 (en) *	1996-01-31	1997-08-07	Steven B. Hansel	A method of making pharmaceutically active taxanes orally bioavailable
FR2764509A1 (fr) *	1997-06-11	1998-12-18	Debiopharm Sa	Compositions pharmaceutiques contenant du dichlorhydrate de cinchonine
FR2784580B1 (fr) *	1998-10-16	2004-06-25	Biosepra Inc	Microspheres de polyvinyl-alcool et procedes de fabrication de celles-ci
AU775373B2 (en)	1999-10-01	2004-07-29	Immunogen, Inc.	Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
WO2003041128A2 (en) *	2001-11-07	2003-05-15	Pharmacia Corporation	Methods of promoting uptake and nuclear accumulation of polyamides in eukaryotic cells
US6916627B2 (en) *	2002-11-27	2005-07-12	St. Jude Children's Research Hospital	ATM kinase compositions and methods
US7108992B2 (en) *	2002-11-27	2006-09-19	St. Jude Children's Research Hospital	ATM kinase compositions and methods
WO2008105872A1 (en) *	2007-02-28	2008-09-04	Cancure Laboratories, Llc	Drug combinations to treat drug resistant tumors
WO2014145386A2 (en) *	2013-03-15	2014-09-18	University Of Florida Research Foundation Incorporated	Novel allosteric inhibitors of thymidylate synthase
CA2891633C (en) *	2014-02-12	2015-12-22	Adam Mickiewicz University	Application of cinchona alkaloid derivatives as cytotoxic compounds
CN105796558A (zh) *	2014-12-31	2016-07-27	天津大学	辛可宁在制备抗肿瘤药物的用途
WO2016209688A1 (en)	2015-06-24	2016-12-29	University Of Florida Research Foundation, Incorporated	Compositions for the treatment of cancer and uses thereof
US11066421B1 (en)	2021-02-09	2021-07-20	Ares Pharmaceuticals, LLC	Synthetic cinchona alkaloids against cancer
US11649232B2 (en)	2021-05-10	2023-05-16	Ares Pharmaceuticals, LLC	Synthetic dimeric cinchona alkaloids against cancer
TR2022004099A2 (tr) *	2022-03-17	2023-09-21	Mugla Sitki Kocman Ueniversitesi Idari Mali Isler Baskanligi	Beyi̇n tümörleri̇ni̇n tedavi̇si̇nde hi̇droki̇ni̇di̇n molekülünün kullanimi
WO2023230702A1 (en) *	2022-06-03	2023-12-07	University Of Manitoba	Novel antimicrobial compounds isolated using a machine learning model trained on a high-throughput antibacterial screen
KR20240119419A (ko) *	2023-01-30	2024-08-06	고려대학교 산학협력단	카이랄 자성 나노코일 및 이의 합성방법

1992
- 1992-02-24 JP JP4507899A patent/JPH06505991A/ja active Pending
- 1992-02-24 CA CA002081343A patent/CA2081343C/fr not_active Expired - Fee Related
- 1992-02-24 EP EP92905338A patent/EP0526608B1/de not_active Expired - Lifetime
- 1992-02-24 WO PCT/EP1992/000408 patent/WO1992014467A1/fr not_active Ceased
- 1992-02-24 DE DE69215999T patent/DE69215999T2/de not_active Expired - Fee Related
- 1992-02-24 ES ES92905338T patent/ES2097905T3/es not_active Expired - Lifetime
- 1992-02-24 AT AT92905338T patent/ATE146361T1/de not_active IP Right Cessation
- 1992-02-24 AU AU12062/92A patent/AU649787B2/en not_active Ceased
1995
- 1995-03-03 US US08/400,415 patent/US5635515A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP0526608B1 (de)	1996-12-18
AU649787B2 (en)	1994-06-02
DE69215999D1 (de)	1997-01-30
EP0526608A1 (de)	1993-02-10
US5635515A (en)	1997-06-03
CA2081343C (fr)	2003-09-16
DE69215999T2 (de)	1997-07-03
AU1206292A (en)	1992-09-15
CA2081343A1 (fr)	1992-08-26
WO1992014467A1 (fr)	1992-09-03
JPH06505991A (ja)	1994-07-07
ES2097905T3 (es)	1997-04-16

Legal Events

Date	Code	Title	Description
1997-06-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE146361T1 (de)	1997-01-15	Therapeutische mittel für die behandlungder resistenz gegen arzneimittel bei krebs
NO20025792D0 (no)	2002-12-02	Kinazolinderivater for behandling av tumorer
BRPI0415525A (pt)	2006-12-26	derivados de imidazola e seu uso como agentes farmacêuticos
IS4073A (is)	1994-03-29	Nýtt fjölvirknislyf gegn aukningu mótstöðu
DE60143857D1 (de)	2011-02-24	Zusammensetzung bestehend aus phy906 und chemotherapeutika
AU2002218167A1 (en)	2002-03-26	N-phenyl-2-pyrimidine-amine derivatives
BRPI0207961A8 (pt)	2017-09-19	Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
DE69323549D1 (de)	1999-03-25	Topisch anwendbare arzneimittel, enthaltend toremifen und dessen metabolite
TR200000576T1 (tr)	2000-11-21	Lipozomal kapsüllenmiş taksan uygulanması için bir yöntem
ATE407928T1 (de)	2008-09-15	Amino-phtalazinon derivate, anwendung als kinase inhibitoren, herstellung und pharmazeutische zusammensetzung
NO20021932D0 (no)	2002-04-24	Medikament egnet til behandling av ondartede tumorer
BR0112591A (pt)	2003-07-22	Derivados de acridina e sua aplicação como medicamento
JP2006500346A5 (de)	2006-08-31
ATE495793T1 (de)	2011-02-15	Antitumorzusammensetzungen welche ecteinascidin 743 enthalten
ATE236147T1 (de)	2003-04-15	Derivate von flavonen, xanthonen und kumarinen
AR043071A1 (es)	2005-07-20	Uso de macrolidos para el tratamiento del cancer y degeneracion macular y una composicion farmaceutica
TR199800270T1 (xx)	1998-05-21	Kanser hastal�klar�n�n ilerlemesini �nlemede flukonazol kullan�m�.
TR200002969T2 (tr)	2001-01-22	Farmasötik bileşim.
NO20044498L (no)	2004-11-04	Kombinasjonsterapi for behandling av cancer
IL165086A (en)	2011-11-30	Pyridyl cyanoguanidines, pharmaceutical compositions comprising them and uses thereof for the preparation of medicaments
DE60327323D1 (de)	2009-06-04	Chinazoline derivative und ihre anwendung in der krebsbehandlung
OA07029A (fr)	1983-12-31	Le chlorure de gallium, nouveau médicament anti-cancéreux.
BR0008305A (pt)	2002-01-22	Utilização de uma proteìna ompa de enterobactéria, ou de um de seus fragmentos e composição farmacêutica
MXPA05010135A (es)	2005-11-16	Nuevos derivados de oxazol, procedimiento para su fabricacion y uso como agentes farmaceuticos.
JP2005513147A5 (de)	2009-06-25